Life sciences firm 'in good health' as revenues rise

A life sciences firm has hailed its growth potential after an “exceptional period” pushed financial performance higher.

Aptamer Group saw unaudited revenue rise 27 per cent to £830,000 in the six months to December 31.

And the York-based operator says it is primed to maintain its momentum thanks to a £2 million-plus order book.

The firm – known for Optimer-branded antibody alternative molecules – says its progress was fuelled by a number of headline agreements that include non-exclusive licensing contracts with Twist Bioscience and Alphazyme.

It is also working with Unilever on a deodorant development programme and recently secured a £617,000 agreement with a ‘top five’ pharmaceutical company to develop its Optimer molecules against three drug targets and support biological sample test advances.

Dr Arron Tolley, Aptamer Group chief executive, said: “This has been an exceptional period as we deliver on our commitments to shareholders. 

“The revenue growth, combined with the signing of multiple licensing agreements, demonstrates the commercial validation of our platform.

“The quality of our partnerships and growing repeat business with top ten pharma partners builds a valuable dual revenue approach, which allows us to take advantage of our operational leverage and positioning as a key leader in the space. 

“We are confident in our ability to continue this positive trajectory and create substantial shareholder value.”

Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →

Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.